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Background: Several studies have been carried out to evaluate the effects of 
dialysis on pulmonary function tests (PFT). Dialysis procedure may reduce 
lung volumes and capacities or cause hypoxia; however, to the best of our 
knowledge, there is no previous study evaluating the effects of membrane type 
(high flux vs. low flux) on PFT in these patients. The aim of this study was the 
evaluation of this relationship. 
Materials and Methods: In this cross-sectional study, 43 hemodialysis patients 
without pulmonary disease were enrolled. In these patients dialysis was 
conducted by low- and high-flux membranes and before and after the 
procedure, spirometry was done and the results were evaluated by t-test and 
chi square test. 
Results: The mean age of patients was 56.34 years. Twenty-three of them were 
female (53.5%). Type of membrane (high flux vs. low flux) had no effect on 
spirometry results of patients despite the significant decrease in the body 
weight during the dialysis session. 
Conclusion: High flux membrane had no advantage over low flux membrane 
in terms of improvement in spirometry findings; thus, we could not offer these 









Hemodialysis can be done by low flux or high flux 
membrane. High-flux dialysis is defined as a β2-
microglobulin clearance of over 20 ml/min (1, 2). High flux 
membranes compared to low flux have larger pores and 
allow diffusion of greater amounts of uremic toxins and 
middle molecules such as β2 microglobuline and therefore 
they may decrease the risk of dialysis-related amyloidosis 
(3, 4).  In addition, these membranes have other 
advantages like increasing patients’ survival (5, 6), reduced 
admission and morbidity (7, 8), less activation of 
coagulation pathway and complement system, less 
leukocytosis and activation of inflammatory system and 
cytokines secretion, removing more endotoxins, better 
lipid profile (9), reduced infection risk, aluminum toxicity 
and better preserved renal function (10-12).  Many studies 
have been done on dialysis patients taking into account 
their pulmonary function tests. Hemodialysis may change 
some of the pulmonary function tests and can decrease 
forced vital capacity (FVC) and forced expiratory volume 
in one second (FEV1). The exact cause of spirometry 
changes in these patients is not completely clear and it may 
be due to the accumulation of WBCs in lung capillaries.  
There are a few studies about PFT in hemodialysis 
patients. High flux membranes compared to low flux ones, 
are more permeable to middle molecules, remove more 
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serum endotoxins, activate inflammatory system less 
frequently and cause less leukocytosis and probably less 
sequestration of leukocytes in pulmonary capillaries, 
which may be responsible for the changes in pulmonary 
function tests. Thus, the present study was conducted to 
compare the acute effects of membrane type on spirometry 
results.    
 
MATERIALS AND METHODS 
Patients:  
In this cross-sectional study, 43 hemodialysis patients 
presenting to Hajar University Hospital in Shahrekord, 
Iran were evaluated. The inclusion criteria were age more 
than 18 years, duration of dialysis for more than 6 months, 
normal chest wall and breath sounds in physical exam and 
ability of patient to perform PFT. Poor compliance, history 
of pulmonary disease, thoracic deformity such as 
kyphoscoliosis, need for oxygen during dialysis and 
previous thoracic surgery were the exclusion criteria.  
 
Dialysis:  
The patents were on dialysis 3 times a week each time 
for 4 hours with Fresenius (Medical care 4008-B, Germany) 
and Gambro (AK 95 S, Swiss) machine. While the patients’ 
blood flow range (QB) was variable from 280 to 350 
ml/min, dialysate flow was constant (500 ml/min). High 
flux dialysis was done by R60 membrane and low flux by 
R6 membrane, both manufactured by Fresenius, Germany. 
Ultrafiltration coefficient of high and low flux membranes 
was 40 and 5.5 cc/hour/mmHg, respectively. Dialysis was 
done by bicarbonate buffer in all sessions. Intra-dialysis 
ultrafiltration was based on patients’ condition.  Patient's 
body weight was also measured before and after dialysis.    
 
Spirometry:  
Hemodialysis was performed by low flux membrane 
and pulmonary function tests (PFT) were done 20 minutes 
before the initiation of dialysis with and without 
bronchodilator (2 puffs of β2 agonist inhaler of 
salbutamol). After dialysis session, PFT was repeated with 
and without bronchodilator in the same patients. In the 
next session, hemodialysis was performed for the same 43 
patients with high flux membrane and PFT was also done 
before and after dialysis as described above. The measured 
spirometry parameters were:  forced vital capacity (FVC), 
forced expiratory volume in the first second (FEV1), 
FEV1/FVC ratio, and maximal mid-expiratory flow rate 
(FEF 25%-75%). Spirometry was done by Winspiro PRO 
2.3, prediction: Crapo and Bass/ Knudson, manufactured 
in Italy. 
 
Statistical analysis:  
Student’s t test was used to compare the PFT values. 
Pearson’s correlation was applied for determination of 
correlations. Data were analyzed using SPSS software 




Twenty-three patients were women (53.5%). The 
causes of renal failure were diabetes mellitus, 
hypertension, hereditary kidney disease and proteinuria in 
23, 14, 3, and 3 patients, respectively. Ischemic heart 
disease was seen in 23 patients and three cases had 
congestive heart failure. The mean age of patients was 
56.34 years (range 23 to 84 yrs.). There were no differences 
in PFT results (FEV1, FVC and FEV1/FVC) before and 
after dialysis with low flux membranes. No differences 
were found in PFT results before and after dialysis with 
high flux membranes either (Table 1). After comparison of 
results, spirometry data with high flux membranes were 
similar to that of low flux membranes before and after 
dialysis (P>0.05). Compared to baseline values before the 
dialysis session, body weight of the patients significantly 
decreased after dialysis due to ultrafiltration during the 
dialysis (P = 0.001). 
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Table 1. Comparison of the characteristics of patients and spirometry results in high and low flux membrane groups. 
 
High Flux Membrane  
 
Low Flux Membrane  
 High Flux versus 
Low Flux Characteristics Time 
Mean± Standard Deviation P  Mean± Standard Deviation P  P 
Before HD* 61.9±12.5 0.001  62.5±12.3 0.001  
Body Weight (kg) 
After HD 59.5±12.1   59.8±12.1   
0.9 
Before HD 129.5±19.3 0.3  125.5±16.9 0.1  
Systolic Blood Pressure (mm Hg) 
After HD 119±19.8   121.3±16.7   
0.5 
Before HD 75.9±8 0.3  73.2±9.1 0.6  
Diastolic Blood Pressure (mm Hg) 
After HD 73.2±9.1   73.9±9   
0.7 
Before HD 1.66±0.7 0.5  1.7±0.8 0.1  
FEV1[without bronchodilator] (lit) 
After HD 1.70±0.6   1.8±0.8   
0.9 
Before HD 1.61±0.7 0.4  1.7±0.8 0.5  
FEV1(lit) [with bronchodilator] 
After HD 1.71±0.6   1.8±0.8   
0.4 
Before HD 1.98±0.9 0.8  2±0.86 0.07  
FVC (lit) [without bronchodilator] 
After HD 1.97±0.7   2.1±0.9   
0.5 
Before HD 1.96±0.8 0.5  2±0.9 0.4  
FVC (lit) [with bronchodilator] 
After HD 1.91±0.7   2±0.9   
0.5 
Before HD 84.7±13.2 0.4  81.1±21.6 0.2  
FEV1/FVC (%) [without bronchodilator] 
After HD 86.5±12.1   85.9±11.5   
0.9 
Before HD 86.1±13.3 0.2  85.8±11.6 0.7  
FEV1/FVC (%) [with bronchodilator] 
After HD 88.5±9.8   86.9±15.8   
0.4 
Before HD 2.1±1 0.8  2.1±1.3 0.9  
FEF 25-75 (lit) [without bronchodilator] 
After HD 2.1±1.1   2.1±1.2   
0.4 
Before HD 2.1±1.1 0.7  2±1.2 0.01  
FEF 25-75 (lit) [with bronchodilator] 





To the best of our knowledge, there is no previous 
study on the relationship between PFT and type of 
membrane. Our results showed that the type of 
hemodialysis membrane has no influence on PFT results. 
There were no significant differences between spirometry 
findings of the two patient groups before and after dialysis 
despite significant ultrafiltration and reduction of body 
weight.  
Several studies have been conducted on the effects of 
hemodialysis on lung volumes and capacities, including 
Hekmat’s study which showed that in hemodialysis 
patients, pulmonary capacities and volumes are less than 
normal population (13). In some studies the correlation of 
weigh reduction and spirometry findings has been 
evaluated; for example, in a study by Alves et al., 61 
dialysis patients were evaluated and spirometry was done 
before and after the dialysis. Improvement of FEV1 and 
FVC after dialysis was correlated with weight loss of 
patients (14). They also concluded that decreased volume 
overload after dialysis is an important factor in 
improvement of PFT findings. Conversely, Langs et al. did 
not find any correlation between lung function parameters 
and intra-dialytic weight loss with cellulose or high flux 
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membrane in 14 hemodialysis patients (15). Our results are 
similar to their study, but the number of our cases was 
three-times higher and we used highly efficient 
biocompatible membrane (R6) instead of cellulose 
membrane.  
In another study conducted by Ferrer et al., comparison 
of spirometry data in patients after dialysis and in normal 
population did not show any significant differences (16). 
Navari et al. in a study on 50 hemodialysis patients 
compared two types of hemodialysis buffer (bicarbonate 
versus acetate) and found that spirometry characteristics 
after dialysis with bicarbonate were higher than acetate in 
male hemodialysis patients independent of intradialytic 
weight reduction (17). Kovacević et al. in a study on 21 
hemodialysis patients reported that only forced expiratory 
flow (FEF50) decreased after 5 years of follow up; however, 
spirometry findings were similar before and after dialysis 
(18). Similarly, Herrero et al. in 5 years follow up of 43 
patients on hemodialysis with bioincompatible membrane 
showed a significant decline in pulmonary diffusing 
capacity possibly due to chronic pulmonary fibrosis (19). 
 
CONCLUSION 
Based on our results, dialysis procedure does not have 
any positive or negative effect on PFT results, despite the 
significant reduction in patients’ weight. In addition, high 
flux membrane had no advantage over low flux membrane 
in terms of improvement of spirometry findings. Thus, we 
could not offer these expensive membranes for this 
purpose.      
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